- Home
- PLL vs GNFT Comparison
PLL vs GNFT Comparison
Compare PLL & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLL
- GNFT
- Stock Information
- Founded
- PLL 2016
- GNFT 1999
- Country
- PLL United States
- GNFT France
- Employees
- PLL N/A
- GNFT N/A
- Industry
- PLL Other Metals and Minerals
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLL Basic Materials
- GNFT Health Care
- Exchange
- PLL Nasdaq
- GNFT Nasdaq
- Market Cap
- PLL 184.1M
- GNFT 186.3M
- IPO Year
- PLL 2017
- GNFT 2019
- Fundamental
- Price
- PLL $8.97
- GNFT $4.23
- Analyst Decision
- PLL Hold
- GNFT Strong Buy
- Analyst Count
- PLL 5
- GNFT 2
- Target Price
- PLL $10.31
- GNFT $11.00
- AVG Volume (30 Days)
- PLL 515.6K
- GNFT 3.9K
- Earning Date
- PLL 08-07-2025
- GNFT 09-22-2025
- Dividend Yield
- PLL N/A
- GNFT N/A
- EPS Growth
- PLL N/A
- GNFT N/A
- EPS
- PLL N/A
- GNFT 0.03
- Revenue
- PLL $105,102,000.00
- GNFT $73,187,701.00
- Revenue This Year
- PLL N/A
- GNFT $5.15
- Revenue Next Year
- PLL $33.37
- GNFT N/A
- P/E Ratio
- PLL N/A
- GNFT $135.73
- Revenue Growth
- PLL 58.18
- GNFT 105.01
- 52 Week Low
- PLL $5.15
- GNFT $2.55
- 52 Week High
- PLL $15.44
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- PLL 55.11
- GNFT 54.95
- Support Level
- PLL $8.48
- GNFT $4.12
- Resistance Level
- PLL $9.44
- GNFT $4.40
- Average True Range (ATR)
- PLL 0.58
- GNFT 0.16
- MACD
- PLL -0.07
- GNFT 0.04
- Stochastic Oscillator
- PLL 34.92
- GNFT 57.23
About PLL Piedmont Lithium Inc.
Piedmont Lithium Inc, is a U.S. based, development-stage, multi-asset, integrated lithium business in support of a clean energy economy and U.S. and world-wide energy security. Its portfolio of wholly-owned projects includes Carolina Lithium, a proposed fully integrated spodumene ore-to-lithium hydroxide project in Gaston County, North Carolina, and Tennessee Lithium, a proposed merchant lithium hydroxide manufacturing plant in McMinn County, Tennessee.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.